MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes

doi:10.3748/wjg.v25.i42.6322

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 42

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9489)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-10) series.

Item

Count

PDF

583

WORD

302

HTML

5307

Figures (1-6)

340

Tables (1-10)

289

Sum=6821

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1055

Download

1613

Sum=2668

Nov 14, 2019 (publication date) through Jan 10, 2025

Times Cited of This Article

Times Cited (22)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Gastroenterol. Nov 14, 2019; 25(42): 6322-6341
Published online Nov 14, 2019. doi: 10.3748/wjg.v25.i42.6322

Full Size Figure Download Figure

Figure 4 A receiver operating characteristic curve analysis for combined panel. A: A receiver operating characteristic (ROC) curve analysis for combined panel for discriminating hepatocellular carcinoma (HCC) out of liver cirrhosis. B: A ROC curve analysis for combined panel for discriminating HCC out of nonmalignant groups. HCC: Hepatocellular carcinoma; LC: Liver cirrhosis.

Citation: Elemeery MN, Mohamed MA, Madkour MA, Shamseya MM, Issa NM, Badr AN, Ghareeb DA, Pan CH. MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes. World J Gastroenterol 2019; 25(42): 6322-6341
URL: https://www.wjgnet.com/1007-9327/full/v25/i42/6322.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i42.6322